Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

Stock Information for Revive Therapeutics Ltd

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Revive Therapeutics Ltd

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
Revive Therapeutics Announces Extension of Proposed Private Placement
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
Revive Therapeutics Announces Proposed Private Placement and Debt Settlement
Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.